The Aceras team has been responsible for funding and supporting the development of a broad range of technologies across the spectrum of medical indications. Aceras’ collective experience spans all aspects of product development, regulatory affairs, corporate finance and strategy. This internal expertise is supplemented by a series of alliances with industry recognized organizations. These ‘strategic partners’ work closely with Aceras to review opportunities, and address the key components necessary for the success of development stage companies. Additionally, Aceras prides itself on carrying out an efficient and transparent assessment of investment opportunities.

With this unique capacity coupled with structural flexibility, Aceras is an attractive alternative to partnering with established pharmaceutical companies and traditional investment firms, and offers various potential avenues of collaboration:

Asset Focused Investment: company creation, product development and financing

Aceras specializes in identifying, acquiring and accelerating the development of novel medical technologies through new and existing portfolio companies it funds, manages and supports.

Aceras pursues partnership opportunities across all therapeutic indications, market sizes, and stages of development and commercialization, through collaborations with companies, research centers and entrepreneurs from around the globe. Aceras has experience working with therapeutic drugs and devices, including small molecules, biologics, New Chemical Entities, and repositioned/reformulated molecules. Aceras performs extensive product candidate reviews to make well informed decisions on which potential programs offer compelling opportunities for patients, physicians, and investors.

In conjunction with a dedicated development team for each project, Aceras is designed to create an effective and successful collaboration with our partners and portfolio companies. Aceras and its strategic partners provide ongoing assistance and guidance to each portfolio company in the selection and execution of an optimal corporate strategy. Our goal is to remove significant risks associated with the clinical, regulatory, manufacturing and financing strategy for each program, resulting in a higher likelihood of success. With this unique capacity and strategy, Aceras is an ideal partner for advancing the development and commercialization of promising medical innovations.

Direct Investments in emerging companies:

The principals at Aceras have decades of collective experience investing in a wide range of transactions with private and public healthcare companies.  This breadth of experience enables the structuring of investments in partnership with management, ensuring that a deal makes sense for all stakeholders and is appropriate for the given situation.  This can take on the form of debt, convertible securities, common equity, revenue participation and variations on these themes.  Unlike traditional venture and institutional investors, Aceras is not wedded to any one structure—it is our belief that structure follows the fundamental investment thesis and that innovative business ideas are not commodities to be squeezed into a “one size fits all” term sheet.